DOR BioPharma, Inc. (AMEX: DOR) ("DOR" or the "Company"),
announced today that it has signed a binding letter of intent to acquire Gastrotech
Pharma A/S ("Gastrotech"), a private Danish biotechnology company
based in Copenhagen, Denmark. Gastrotech develops therapeutics based on peptide
hormones to treat cancer and gastrointestinal (GI) diseases and conditions.
Gastrotech was founded on technology developed at the Sahlgrenska University
Hospital in Sweden which is known as the development cradle of Growth Hormone
and IGF-1 research.
Genetic Engineering News